Precipio (NASDAQ:PRPO) Rating Lowered to Hold at Wall Street Zen

Precipio (NASDAQ:PRPO) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Precipio in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Precipio has an average rating of “Sell”.

Precipio Trading Up 3.5%

Shares of PRPO opened at $27.88 on Friday. The business’s 50-day moving average price is $24.65 and its 200 day moving average price is $22.43. The company has a current ratio of 1.27, a quick ratio of 1.10 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $48.79 million, a P/E ratio of -34.00 and a beta of 1.22. Precipio has a 1-year low of $3.90 and a 1-year high of $29.53.

Institutional Trading of Precipio

Several hedge funds and other institutional investors have recently modified their holdings of PRPO. Topline Capital Management LLC purchased a new position in shares of Precipio during the third quarter valued at $1,158,000. AMH Equity Ltd lifted its stake in Precipio by 370.1% in the 3rd quarter. AMH Equity Ltd now owns 131,100 shares of the biotechnology company’s stock worth $2,332,000 after acquiring an additional 103,210 shares in the last quarter. Evernest Financial Advisors LLC purchased a new stake in Precipio in the 3rd quarter worth about $374,000. Geode Capital Management LLC boosted its position in Precipio by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after acquiring an additional 789 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Precipio by 10.7% during the 4th quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock worth $333,000 after acquiring an additional 1,400 shares during the period. Institutional investors and hedge funds own 10.45% of the company’s stock.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.